# Role of the RBMS Family in Different Cancers and Research Progress

**Authors:** Hanchi Wu, Rui Hou, Yuhan Zhang, Hanfang Fan, Junying Xu, Huiyu Wang

PMC · DOI: 10.7150/ijms.118386 · 2026-01-23

## TL;DR

This paper reviews how RNA-binding motif single-stranded interacting proteins (RBMSs) influence cancer development and progression in various types of cancer.

## Contribution

The paper provides a comprehensive review of RBMS family roles in multiple cancers and their regulatory mechanisms.

## Key findings

- RBMS proteins regulate oncogenes, growth factors, and cell cycle proteins in cancer.
- RBMSs are involved in tumorigenesis and tumor progression across several cancer types.
- The paper summarizes current research on RBMSs in breast, prostate, lung, liver, gastric, and colorectal cancers.

## Abstract

RNA-binding proteins (RBPs), as posttranscriptional regulators, can modulate the activity and stability of target RNAs and participate in the whole life cycle of RNA processing, localization, modification and translation. RNA-binding motif single-stranded interacting proteins (RBMSs) comprise a critical subgroup within the RNA-binding protein (RBP) family, sharing the same domain characteristics as other RBPs. Several studies have shown that RBMSs can participate in tumorigenesis and tumor progression through mechanisms such as regulating the expression of oncogenes, growth factors and cell cycle proteins. In this paper, we reviewed the role of RBPs and related research progress in breast, prostate, lung, liver, gastric and colorectal cancers.

## Linked entities

- **Proteins:** RENBP (renin binding protein)
- **Diseases:** breast cancer (MONDO:0004989), prostate cancer (MONDO:0005159), lung cancer (MONDO:0005138), liver cancer (MONDO:0002691), gastric cancer (MONDO:0001056), colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** AXIN1 (axin 1) [NCBI Gene 8312] {aka AXIN, CMDOH, PPP1R49}, EIF3D (eukaryotic translation initiation factor 3 subunit D) [NCBI Gene 8664] {aka EIF3S7, eIF3-p66, eIF3-zeta}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TWIST1 (twist family bHLH transcription factor 1) [NCBI Gene 7291] {aka ACS3, BPES2, BPES3, CRS, CRS1, CSO}, LINC01094 (long intergenic non-protein coding RNA 1094) [NCBI Gene 100505702] {aka CTEPHA1}, SDCBP (syndecan binding protein) [NCBI Gene 6386] {aka MDA-9, MDA9, SDCBP1, ST1, SYCL, TACIP18}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, EIF4E (eukaryotic translation initiation factor 4E) [NCBI Gene 1977] {aka AUTS19, CBP, EIF4E1, EIF4EL1, EIF4F, eIF-4E}, LINC00525 (long intergenic non-protein coding RNA 525) [NCBI Gene 84847], MIR4442 (microRNA 4442) [NCBI Gene 100616477] {aka mir-4442}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, KCNQ1OT1 (KCNQ1 opposite strand/antisense transcript 1) [NCBI Gene 10984] {aka KCNQ1-AS2, KCNQ10T1, Kncq1, KvDMR1, KvLQT1-AS, LIT1}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, BMF (Bcl2 modifying factor) [NCBI Gene 90427], NFAT5 (nuclear factor of activated T cells 5) [NCBI Gene 10725] {aka NF-AT5, NFATL1, NFATZ, OREBP, TONEBP}, EXOC6B (exocyst complex component 6B) [NCBI Gene 23233] {aka SEC15B, SEC15L2, SEMDJL3}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, RBMS2 (RNA binding motif single stranded interacting protein 2) [NCBI Gene 5939] {aka SCR3}, CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}, VIM (vimentin) [NCBI Gene 7431], AKAP12 (A-kinase anchoring protein 12) [NCBI Gene 9590] {aka AKAP250, SSeCKS}, BACH1 (BTB domain and CNC homolog 1) [NCBI Gene 571] {aka BACH-1, BTBD24}, DKK3 (dickkopf Wnt signaling pathway inhibitor 3) [NCBI Gene 27122] {aka CRRL, REIC, RIG}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, RBMS3 (RNA binding motif single stranded interacting protein 3) [NCBI Gene 27303], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, MIR106B (microRNA 106b) [NCBI Gene 406900] {aka MIRN106B, mir-106b}, RBMS1 (RNA binding motif single stranded interacting protein 1) [NCBI Gene 5937] {aka C2orf12, HCC-4, MSSP, MSSP-1, MSSP-2, MSSP-3}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, Rbms3 (RNA binding motif, single stranded interacting protein) [NCBI Gene 207181] {aka 6720477E09Rik, 8430436O14Rik}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, PRRX1 (paired related homeobox 1) [NCBI Gene 5396] {aka AGOTC, PHOX1, PMX1, PRX-1, PRX1}, MIR1265 (microRNA 1265) [NCBI Gene 100302116] {aka MIRN1265, hsa-mir-1265}, ELAVL1 (ELAV like RNA binding protein 1) [NCBI Gene 1994] {aka ELAV1, HUR, Hua, MelG}, SFRP1 (secreted frizzled related protein 1) [NCBI Gene 6422] {aka FRP, FRP-1, FRP1, FrzA, SARP2}, EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}
- **Diseases:** gynecological malignancies (MESH:D005833), tumor suppressor (OMIM:601308), Metastasis (MESH:D009362), death (MESH:D003643), Colon cancer (MESH:D015179), Hepatocellular carcinoma (MESH:D006528), necrosis (MESH:D009336), breast cancer (MESH:D001943), triple-negative breast cancer (MESH:D064726), lymph node metastasis (MESH:D008207), ovarian cancer (MESH:D010051), Lung cancer (MESH:D008175), Cancer (MESH:D009369), Prostate cancer (MESH:D011471), reproductive system tumors (MESH:D060737), non-small cell lung cancer (MESH:D002289), lung adenocarcinoma (MESH:D000077192), castration-resistant (MESH:D064129), Gastric cancer (MESH:D013274), carcinogenesis (MESH:D063646), epithelial ovarian cancer (MESH:D000077216)
- **Chemicals:** MTT (MESH:C070243), CDDP (-), cisplatin (MESH:D002945), doxorubicin (MESH:D004317), cystine (MESH:D003553), PRI-724 (MESH:C492448), glutathione (MESH:D005978), lipid (MESH:D008055), platinum (MESH:D010984), nortriptyline hydrochloride (MESH:D009661), iron (MESH:D007501), TSA (MESH:C012589)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** BRAFV600E, L858R
- **Cell lines:** SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546), LNCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0395), LS174T — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_1384), SUM-1315 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_5589), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), DU145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12964577/full.md

---
Source: https://tomesphere.com/paper/PMC12964577